Why the study?
Do low molecular weight heparins prevent thromboembolic complications in patients with malignant neoplasms?
Do low molecular weight heparins prevent thromboembolic complications in patients with malignant neoplasms?
Low molecular weight heparins are essential for preventing venous thromboembolism and fatal pulmonary embolism in cancer patients undergoing surgery or chemotherapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Сомонова et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: